Haemonetics Aktie
WKN: 881782 / ISIN: US4050241003
|
08.08.2024 12:21:35
|
Haemonetics Q1 Profit Slips, Despite Revenue Growth, Reaffirms FY25 Adj. EPS, Revenue Range
(RTTNews) - Haemonetics Corp. (HAE) Thursday announced a 6.5 percent decline in first quarter earnings, despite an 8 percent increase in revenue, compared to the prior year.
The quarterly earnings were $38.37 million or $0.74 per share, down from $41.04 million or $0.80 per share last year. On an adjusted basis, earnings were $1.02 per share.
The amortization of fair value inventory step-up related to the Attune Medical acquisition, restructuring costs, and higher Operating expenses impacted the decline of profit.
On average, 7 analysts polled by Thomson Reuters expected the company to earn $1 per share. Analysts estimte usually exclude special items.
Revenue for the first quarter came in to $336.17 million, from $311.33 million a year ago. Wall Street were looking for $335.38 million.
Looking ahead to the fiscal 2025, the company reaffirmed adjusted earnings per share guidance in a range of $4.45-$4.75 per share. Total revenue guidance is affirmed in a range of 5-8 percent. Analysts expect the fiscal earnings of $4.6 per share on revenue of $1.4 billion.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Haemonetics Corp.mehr Nachrichten
|
05.11.25 |
Ausblick: Haemonetics verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
|
22.10.25 |
Erste Schätzungen: Haemonetics vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
|
06.08.25 |
Ausblick: Haemonetics zieht Bilanz zum abgelaufenen Quartal (finanzen.net) | |
|
23.07.25 |
Erste Schätzungen: Haemonetics stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) |
Analysen zu Haemonetics Corp.mehr Analysen
Aktien in diesem Artikel
| Haemonetics Corp. | 57,50 | 0,88% |
|